By Dr. Sandra Langer, Fujirebio
Welcome to a new series of Insight posts about KL-6 in Lung Diseases!
Interstitial lung diseases (ILDs) represent a large, heterogeneous group of more than 200 different entities, most of which are classified as rare diseases.
Accurate diagnosis of Idiopathic Pulmonary Fibrosis (IPF) is critical, as other forms of ILD that have similar clinical presentations to IPF require different treatment strategies.
Imaging plays an essential role in the diagnosis of ILDs.
Several scientific authors deal with the idea of combining IPF with other forms of fibrosing ILD that have, i.e. self-sustaining fibrosis, progressive decline in lung function, and early mortality in the group of “progressive fibrosing ILDs” that would describe ILD in patients who, independent of the classification of the ILD, at some point in time exhibit a progressive fibrosing phenotype.
Pulmonary function parameters at a single time point do not reliably predict disease behavior and, despite multiple attempts, High resolution computer tomography (HRCT)-quantified disease extent on sequential imaging has not been established as a reliable marker of disease progression.
Based on the results from a number of reports investigating Krebs von den Lungen-6 / Mucin 1 (KL-6/MUC1), the serum levels of KL-6/MUC1 are useful for 1) detecting the presence of disease, 2) evaluating disease activity, and 3) predicting outcomes in various types of ILDs.
Read the first post below or download the complete guidance document now!
You can follow our Insight articles over the next weeks and get some deeper information on the value of measuring KL-6 in the field of lung diseases. But you can also directly download the complete guidance document right away, following this link (requires a Premium eServices account).
We are always happy to hear comments and questions on this topic, so feel free to contact us. Many thanks!
Current Classification of interstitial lung diseases
- ILD early and accurate diagnosis is challenging due to heterogeneity of the disease.
- Even with multidisciplinary team assessment, 15-25% of ILD patients remain unclassifiable.
Interstitial lung diseases (ILDs) represent a large, heterogeneous group of more than 200 different entities, most of which are classified as rare diseases. They are defined as lung diseases that affect the alveolar structures, the pulmonary interstitium, and small airways. The current diagnosis of an ILD relies mainly on the combination of clinical, radiological, and pathological criteria, which should be explored in a multidisciplinary board.2
Even if Interstitial Pulmonary Fibrosis (IPF) can be seen as the largest group within ILDs it has been shown that approximately one in 10 patients has an unclassifiable ILD. This makes it the fourth most common classification behind IPF (21%), hypersensitivity pneumonitis (15%) and sarcoidosis (14%).3
- Bendstrup, Elisabeth, et al. "Challenges in the classification of fibrotic ILD." Sarcoidosis vasculitis and diffuse lung disease 32.1S (2015): 4-9.
- Kokosi, Maria A., George A. Margaritopoulos, and Athol U. Wells. "Personalised medicine in interstitial lung diseases: Number 6 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche." European Respiratory Review 27.148 (2018): 170117.
- Ryerson, Christopher J., et al. "Prevalence and prognosis of unclassifiable interstitial lung disease." European Respiratory Journal 42.3 (2013): 750-757.
Don't miss the next posts on this topic in the following weeks:
- ILD diagnosis – current professional practice
- Use of serum biomarkers in progressive fibrosing ILDs
- KL-6 in disease prognosis
- From Classification to disease activity